iifl-logo-icon 1
iifl-logo-icon 1Budget 2024
iifl-logo-icon 1
Home

J B Chemicals & Pharmaceuticals Ltd Board Meeting

₹1,825.2
(0.73%)
Jul 23, 2024|03:32:34 PM

J B Chemicals & CORPORATE ACTIONS

24/07/2023calendar-icon
23/07/2024calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting17 May 202410 May 2024
J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2024 inter alia to consider and approve (i) the audited financial results for the year and quarter ended on March 31 2024; (ii) Consider and recommend Dividend on equity shares of the Company if any subject to approval of shareholders Recommendation of Final dividend of Rs. 6.75 per share of FV Re. 1(675%) for the FY 2023-24 (As Per BSE Announcement Dated on 15.05.2024)
Board Meeting6 Feb 202430 Jan 2024
J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2024 inter alia to consider and approve (1) Unaudited Financial Results for the quarter and nine months ended on December 31 2023; and (2) Declaration of Interim Dividend if any for the financial year 2023-24 Declaration of interim dividend of Rs. 5.50 per share(550%) for Fy 2023-24 Appointment of Chief Financial Officer (As Per BSE Announcement Dated on 06.02.2024)
Board Meeting7 Nov 202330 Oct 2023
J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 inter alia to consider and approve unaudited financial results for the quarter and half year ended on September 30 2023 Unaudited financial results for the quarter and half year ended on September 30, 2023 accompanied by limited review report Appointment of Non-Executive Director Amendment to the Employee Stock Option Scheme Grant of Options under Employee Stock Option Scheme Allotment of Equity shares on exercise of Stock options pursuant to the Employee Stock Scheme (As Per BSE Announcement Dated on 07/11/2023) Newspaper cutting of extract of consolidated financial results for the quarter and half year ended on September 30, 2023 (As Per BSE Announcement Dated on 08/11/2023)
Board Meeting9 Aug 20231 Aug 2023
J.B.CHEMICALS & PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2023 inter alia to consider and approve unaudited financial results for the quarter ended on June 30 2023. Unaudited Financial Results for the quarter ended on June 30, 2023 Setting-up of proposed step-down subsidiary Grant of options under Employee stock option scheme (As Per BSE Announcement Dated on 09.08.2023)

J B Chemicals &: Related News

No record found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

QUICKLINKS FOR J B Chemicals & Pharmaceuticals Ltd

Information
Share PriceFutures PriceOption Chain
Financials
Profit & LossBalance SheetCash FlowKey Ratios
Results
Quarterly ResultHalf Yearly ResultNine Monthly ResultAnnual Result
News
Company
Marketplus
Derivativesplus
IPOplus
Mutual Fundsplus
Calculatorsplus
Nifty 50plus
Companyplus
Loansplus
Knowledge Centerplus
Newsplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Marketplus
Derivativesplus
IPOplus
Mutual Fundsplus
Calculatorsplus
Nifty 50plus
Companyplus
Loansplus
Knowledge Centerplus
Newsplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

About
IIFL Group
Products & Services
Trading Documentation
Useful Links
ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.